The FDA removed the boxed warnings from menopausal hormone therapy

Major development · 2025–2026

On 10 November 2025 the FDA and HHS announced they would initiate removal of the broad boxed "black box" warnings from hormone therapy products for menopause. On 12 February 2026 the FDA approved the first batch of six revised labels, removing the risk statements for cardiovascular disease, breast cancer and probable dementia. Twenty-nine manufacturers had submitted proposed label changes by that date.

What did not change: the boxed warning for endometrial cancer on systemic estrogen-alone products in women with a uterus remains. Progestogen is still required to protect the endometrium.

What it means, and what it does not. Those warnings came from the 2002 Women's Health Initiative results — a trial whose participants averaged 63 years of age, more than a decade past menopause, using a formulation that is no longer standard. Applying that finding to a symptomatic 51-year-old was always a misreading, and it left two decades of women undertreated. Correcting the label corrects the misreading. It does not make hormone therapy right for everyone, it does not abolish individual contraindications, and it does not turn a symptom treatment into an anti-ageing intervention. The decision remains individual, and it still belongs in a conversation with your own clinician.

Sources: FDA/HHS news release, 10 November 2025; FDA news release, 12 February 2026. Full citations on the references page.